Published in Drugs on May 01, 1995
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care (1999) 16.79
A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother (1999) 1.58
Inositols in the Treatment of Insulin-Mediated Diseases. Int J Endocrinol (2016) 1.40
Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis (2012) 1.28
Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean J Intern Med (2010) 1.25
Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care (2010) 1.23
Diabetes, related conditions, and dementia. J Neurol Sci (2010) 1.08
Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol (2006) 1.03
Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci (2013) 0.94
The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: The Fremantle Diabetes Study. Br J Clin Pharmacol (2001) 0.90
Severe metformin intoxication with lactic acidosis in an adolescent. Eur J Pediatr (2005) 0.82
Formulation and evaluation of a sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers. Indian J Pharm Sci (2011) 0.82
Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. Nephron (2016) 0.81
Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. J Diabetes Res (2016) 0.80
Transporter-mediated drug-drug interactions with oral antidiabetic drugs. Pharmaceutics (2011) 0.79
Population PK/PD analysis of metformin using the signal transduction model. Br J Clin Pharmacol (2012) 0.78
Study on sustained-release metformin hydrochloride from matrix tablet: Influence of hydrophilic polymers and in vitro evaluation. Int J Pharm Investig (2011) 0.77
Metformin inhibits Branched Chain Amino Acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD. Sci Rep (2016) 0.76
Metformin treatment in hyperglycemic critically ill patients: another challenge on the control of adverse outcomes. Iran J Pharm Res (2011) 0.76
Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial. J Alzheimers Dis (2016) 0.76
Apoptosis in pancreatic β-islet cells in Type 2 diabetes. Bosn J Basic Med Sci (2016) 0.76
Multivariate chemometric assisted analysis of metformin hydrochloride, gliclazide and pioglitazone hydrochloride in bulk drug and dosage forms. Adv Pharm Bull (2013) 0.75
Fighting obesity: When muscle meets fat. Adipocyte (2014) 0.75
Design and In-vitro Evaluation of Sustained Release Floating Tablets of Metformin HCl Based on Effervescence and Swelling. Iran J Pharm Res (2016) 0.75
Drug interactions, renal impairment and hypoglycaemia in a patient with Type II diabetes. Br J Clin Pharmacol (1999) 0.75
Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients. Neoplasia (2017) 0.75
Response surface optimization of sustained release metformin-hydrochloride matrix tablets: influence of some hydrophillic polymers on the release. ISRN Pharm (2012) 0.75
Medication Use Among Patients Prior to Bariatric Surgery. Bariatr Surg Pract Patient Care (2015) 0.75
Regular use of alcohol and tobacco in India and its association with age, gender, and poverty. Drug Alcohol Depend (2005) 1.90
The determinants of use of maternal and child health services in Metro Cebu, the Philippines. Health Transit Rev (1993) 1.42
Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs (1994) 1.32
Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs (1997) 1.01
Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1995) 1.00
Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 0.98
Comparative analysis of exit interviews and direct clinical observations in pediatric ambulatory care services in Afghanistan. Int J Qual Health Care (2010) 0.98
Loratadine. A reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs (1994) 0.97
Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs (1996) 0.95
Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs (1993) 0.91
Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs (1996) 0.89
Cyst of seminal vesicle with ipsilateral renal agenesis and ectopic ureter: case report. J Urol (1976) 0.88
Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs (1997) 0.88
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs (1997) 0.86
Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs (1994) 0.86
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging (1994) 0.84
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs (1995) 0.82
Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs (1995) 0.80
When is fever malaria? Lancet (1992) 0.80
Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris. Drugs Aging (1995) 0.78
Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. Pharmacoeconomics (1996) 0.78
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs (1995) 0.77
Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Drugs Aging (1996) 0.77
Awareness of anti-malarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states. Afr J Med Med Sci (2011) 0.77
Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs (1996) 0.75
Improvement of therapeutic drug monitoring. QA Rev (1992) 0.75
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections. Drugs (1995) 0.75
Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients. Drugs Aging (1995) 0.75